Maillinckrodt Medical Licenses Invention For Concentration Of Rhenium Radioisotopes

January 20, 1998

OAK RIDGE, Tenn., Jan. 20, 1997 --Mallinckrodt Medical Inc. has licensed an invention from the Department of Energy's (DOE) Oak Ridge National Laboratory (ORNL) that could save more than 100,000 people from having additional heart surgery.

Of the 400,000 balloon angioplasty procedures that are performed annually in the United States, 30 percent of patients require additional surgery because their arteries clog up again, but the use of a special radioactive isotope -- rhenium-188 -- prevents this arterial blockage from forming.

Rhenium 188 is available from the tungsten-188/rhenium-188 generator developed in the ORNL Nuclear Medicine program.

Although a variety of pharmacological approaches are being explored to inhibit restenosis after balloon angioplasty, ionizing radiation has been found to be one of the only non-surgical and easily performed procedures which is effective. This can be accomplished using the technology developed at ORNL and licensed to Mallinckrodt.

A highly concentrated form of rhenium is needed for this type of procedure and is provided by a special ion exchange system developed at ORNL. The concentration method, developed by researchers at the laboratory, uses rhenium-188 for the radiation of the coronary arteries after angioplasty. Rhenium treatment following balloon angioplasty cuts the rate of restenosis, or reblockage of the arteries, significantly.

The licensing agreement gives the St. Louis-based company sole commercial, field-of-use rights for the invention. With restenosis occurring in 25 percent to 30 percent of angioplasty patients, "the invention will help save time, lives and costs -- for both hospitals and patients," said Russ Knapp, principal investigator who led the team.

The technology was developed at ORNL by Knapp, Arnold Beets, Saed Mirzadeh and Stefan Guhke of the Life Sciences Division. Robert Mills, vice president and general manager of Mallinckrodt Interventional, said that Mallinckrodt is excited about obtaining the license "because it expands our capabilities in working with rhenium radioisotopes."

Knapp emphasized this new use of rhenium 188 is a cost-effective alternative to other radioisotopes. Besides treating restenosis, rhenium-188 is used in physician-approved trials in collaboration with ORNL for the treatment of bone pain from skeletal metastases of cancers of the breast, lung and prostate.

The clinical application of rhenium-188 for coronary artery irradiation has been approved by the U.S. Food and Drug Administration for use at Columbia University Medical Center in New York. The first patient was treated in September. Sixty patients will be enrolled in this Phase I study. Initial results will be available early this year.

Mallinckrodt, established in 1867, is an international radiopharmaceutical manufacturer with corporate offices and research and production facilities located in St. Louis. Mallinckrodt has eight business divisions serving markets in human health care, animal health and specialty chemicals.

"This is a perfect example of how a partnership between private business and government can lead to something that can benefit thousands of people and improve their quality of life," Knapp said.

ORNL, one of DOE's multiprogram research facilities, is managed by Lockheed Martin Energy Research Corporation.
Written by Courtney Wilson

If you would prefer to receive your news release by e-mail, please send your e-mail address to

You may read other news releases from Oak Ridge National Laboratory or learn more about the Lab if you have access to the Internet. You can find our information on the World Wide Web at
category: isotopes, technology

DOE/Oak Ridge National Laboratory

Related Angioplasty Articles from Brightsurf:

Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor.

Study finds significant variability in doctors' angioplasty death rates
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI); however, doctors should not be judged solely on the rate of patients who die from the procedure.

Beta-blockers following angioplasty show little benefit for some older patients
Following coronary angioplasty, beta-blockers did not significantly improve mortality rates or reduce the number of future cardiovascular incidents for older patients with stable angina but no history of heart attack or heart failure, according to a study published today in the JACC: Cardiovascular Interventions.

Sleep disorders may predict heart events after angioplasty
People who have had procedures to open blocked heart arteries after acute coronary syndrome (ACS) may have a higher risk of death, heart failure, heart attack and stroke if they have sleep disorders, such as sleep apnea, compared to those who don't.

Reasons for hospital-level variations in bleeding post-angioplasty are unclear
The use of bleeding avoidance strategies has only a modest effect on the variation in bleeding rates post-angioplasty among hospitals performing this procedure, leaving about 70 percent of the causes for this variation unexplained, according to a study published today in JACC: Cardiovascular Interventions.

US prediction models for kidney injury following angioplasty hold up in Japan
Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan.

IV beta blockers before angioplasty are safe, but offer no clinical benefit
Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack -- ST-segment elevation myocardial infarction (STEMI) -- was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

Life-threatening bowel ischemia can often be treated by balloon angioplasty
Acute mesenteric ischemia (AMI) can be successfully treated with endovascular therapy such as balloon angioplasty, according to research from the University of Eastern Finland.

Radial access used less than femoral approach for emergency angioplasty
Although using the radial artery as the access point for angioplasty has been linked to reduced bleeding compared to use of the femoral artery, only a small number of high-risk heart attack patients who undergo rescue angioplasty -- emergency procedures following failed therapy with clot-busting drugs -- are treated by radial access, according to a study published today in the Journal of the American College of Cardiology: Cardiovascular Interventions.

Use of rarely appropriate angioplasty procedures declined sharply
The number of angioplasty procedures classified as rarely appropriate declined sharply between 2010 and 2014, as did the number of those performed on patients with non-acute conditions, according to a study published today in the Journal of the American Medical Association and simultaneously presented at a meeting of the American Heart Association in Orlando.

Read More: Angioplasty News and Angioplasty Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to